Royal Bank Of Canada Reaffirms Buy Rating for Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (NASDAQ:KPTI)‘s stock had its “buy” rating reissued by Royal Bank Of Canada in a research report issued to clients and investors on Friday. They presently have a $15.00 target price on the stock. Royal Bank Of Canada’s target price would indicate a potential upside of 33.57% from the stock’s previous close.
KPTI has been the subject of several other reports. Canaccord Genuity set a $18.00 target price on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a research note on Tuesday, August 8th. BidaskClub raised shares of Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 9th. Jefferies Group LLC reissued a “buy” rating and set a $19.00 target price (up from $16.00) on shares of Karyopharm Therapeutics in a research note on Thursday, August 10th. Robert W. Baird reissued a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday. Finally, ValuEngine lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. Karyopharm Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $15.50.
Shares of Karyopharm Therapeutics (NASDAQ KPTI) traded up $0.87 during trading hours on Friday, hitting $11.23. 2,269,911 shares of the stock were exchanged, compared to its average volume of 175,660. Karyopharm Therapeutics has a 12 month low of $6.27 and a 12 month high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 75.03% and a negative net margin of 67,267.47%. research analysts anticipate that Karyopharm Therapeutics will post -2.65 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Royal Bank Of Canada Reaffirms Buy Rating for Karyopharm Therapeutics Inc. (KPTI)” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/11/04/royal-bank-of-canada-reaffirms-buy-rating-for-karyopharm-therapeutics-inc-kpti-2.html.
In other news, Director Mansoor Raza Mirza sold 2,882 shares of the stock in a transaction on Friday, September 15th. The shares were sold at an average price of $11.00, for a total transaction of $31,702.00. Following the transaction, the director now owns 2,882 shares in the company, valued at approximately $31,702. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders sold 10,695 shares of company stock worth $118,950. Company insiders own 14.71% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in KPTI. Metropolitan Life Insurance Co. NY acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth $136,000. Voya Investment Management LLC boosted its holdings in shares of Karyopharm Therapeutics by 42.1% during the 2nd quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after buying an additional 4,444 shares during the period. Tudor Investment Corp ET AL bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth $136,000. Endurance Wealth Management Inc. boosted its holdings in shares of Karyopharm Therapeutics by 166.7% during the 3rd quarter. Endurance Wealth Management Inc. now owns 16,000 shares of the company’s stock worth $156,000 after buying an additional 10,000 shares during the period. Finally, Bank of Montreal Can bought a new stake in shares of Karyopharm Therapeutics during the 3rd quarter worth $159,000. Institutional investors own 59.10% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.